Alkermes (ALKS) Cash from Investing Activities (2010 - 2026)
Alkermes' (ALKS) quarterly Cash from Investing Activities came in at -$2.4 million in Q2 2026, up 91.75% year-over-year from -$1.3 million in Q2 2025, and up 99.88% quarter-over-quarter from -$2.1 billion in Q1 2026.
Analysis
Alkermes (ALKS) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Cash from Investing Activities for 17 consecutive years, with -$2.4 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash from Investing Activities rose 91.75% year-over-year to -$2.4 million in Q2 2026; TTM through Jun 2026 was -$1.8 billion, a 1130.68% decrease from a year earlier, with the FY2025 full-year figure at $295.5 million, up 365.48% from the prior year.
- Cash from Investing Activities was -$2.4 million for Q2 2026 at Alkermes, up from -$2.1 billion in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $322.3 million in Q4 2025 and troughed at -$2.1 billion in Q1 2026.
- A 5-year average of -$105.9 million and a median of -$10.3 million in 2024 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities surged 3838.54% in 2022 and plunged 22919.16% in 2026, its largest moves.
- Over 5 years, Cash from Investing Activities stood at $27.7 million in 2022, then slumped by 175.64% to -$21.0 million in 2023, then jumped by 33.87% to -$13.9 million in 2024, then jumped by 2423.21% to $322.3 million in 2025, then slumped by 100.75% to -$2.4 million in 2026.
- The last three Cash from Investing Activities figures came in at -$2.4 million (Q2 2026), -$2.1 billion (Q1 2026), and $322.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | -1.11 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -1.20 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -5.60 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -3.11 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.11 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -424.26 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | -1.66 Bn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | -51.79 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 87.50 Mn |
| 10 | Alkermes | 7.58 Bn | 6.92 Bn | 397.90 Mn | -2.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.41 Mn |
| Mar 31, 2026 | -2.08 Bn |
| Dec 31, 2025 | 322.35 Mn |
| Sep 30, 2025 | -6.74 Mn |
| Jun 30, 2025 | -29.21 Mn |
| Mar 31, 2025 | 9.10 Mn |
| Dec 31, 2024 | -13.88 Mn |
| Sep 30, 2024 | -109.33 Mn |
| Jun 30, 2024 | 51.85 Mn |
| Mar 31, 2024 | -39.95 Mn |
| Dec 31, 2023 | -20.98 Mn |
| Sep 30, 2023 | -119.36 Mn |
| Jun 30, 2023 | 120.85 Mn |
| Mar 31, 2023 | 72.85 Mn |
| Dec 31, 2022 | 27.74 Mn |
| Sep 30, 2022 | 8.90 Mn |
| Jun 30, 2022 | -40.54 Mn |
| Mar 31, 2022 | -60.64 Mn |
| Dec 31, 2021 | -742,000.00 |
| Sep 30, 2021 | -31.71 Mn |